All three phases of nōuxx Cycle Routine contain 2,000 mg of myo-inositol.
Myo-inositol is a compound your body makes and that is also found in food. Inositol-containing molecules participate in cellular signalling, including pathways linked to insulin. This is one reason researchers study it in PCOS.[2]
That dual role on the insulin pathway and the FSH pathway is why myo-inositol has been studied in women with polycystic ovary syndrome. PCOS sits at the intersection of insulin resistance and disordered ovulation. A molecule that touches both makes biological sense as a research target.[2]
Forms of inositol
Inositol has several forms. Myo-inositol and D-chiro-inositol are the forms most often discussed in PCOS research. Trials have studied them alone and in combinations, including a 40:1 ratio. A ratio used in a supplement is not proof that it is the best option for every woman.[2]
nōuxx Cycle Routine uses myo-inositol on its own. The international PCOS guideline does not recommend a particular form, dose or combination because high-quality comparative evidence is lacking.[1]
How much you need
The amount used in a study is not automatically a daily requirement. For PCOS, the guideline recommends discussing individual goals and the uncertainty of the evidence with a healthcare professional.[1]
Each daily sachet of nouxx Cycle Routine contains 2,000 mg of myo-inositol. Follow the serving instructions on the pack. Clinical study protocols do not establish a reason to take additional sachets.
The PCOS trials in the 2023 review used different treatment periods, including 12, 16 and 24 weeks. These study schedules do not establish a universal minimum time to benefit or predict a response for an individual woman.[3]
The science on women's health
PCOS and hormonal regulation
The strongest body of research on myo-inositol in women is in PCOS. A 2024 systematic review and meta-analysis informing the international evidence-based PCOS guidelines included 30 trials involving 2,230 women, with 19 contributing to meta-analyses. Inositol showed benefit on several metabolic measures. The reviewers also flagged that the evidence base is heterogeneous and that confidence in any single outcome remains limited.[2]
A 2023 meta-analysis of 26 trials involving 1,691 women with PCOS reported improvements in cycle regularity and some metabolic or hormonal measures compared with placebo. Results varied by outcome. Its comparisons with metformin do not establish that the two treatments are interchangeable. The later guideline review judged the overall evidence limited and inconclusive.[3][2]
Fertility and assisted reproduction
A 2025 review of 11 studies involving 981 women undergoing IVF found a higher proportion of mature oocytes and a higher fertilisation rate with myo-inositol. These laboratory outcomes do not establish a higher live-birth rate. The authors called for better-quality prospective trials, and the PCOS guideline considers inositol experimental as a fertility treatment.[4][1]
Beyond PCOS, the evidence in eumenorrheic women is thin. Most trials have been done in women with a diagnosis of PCOS or in women preparing for fertility treatment. The 2023 Cochrane review of antenatal myo-inositol supplementation in 1,319 pregnant women suggested a reduction in gestational diabetes incidence, with the authors noting low certainty and the need for larger trials.[5] These pregnancy studies do not establish that Cycle Routine is suitable during pregnancy. Discuss supplements in pregnancy with your maternity care team.
EU authorised health claims
Under EU law, no specific health claim is currently authorised for myo-inositol.
Research in PCOS suggests possible benefits for some metabolic measures, but evidence for clinical outcomes remains uncertain. Findings from women with PCOS cannot be assumed to apply to women with regular cycles and no PCOS diagnosis.[2]
References
[1] Teede HJ, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Full guideline, sections 4.7 and 5.8.
[2] Fitz V, Graca S, Mahalingaiah S, et al. Inositol for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 update of the international evidence-based PCOS guidelines. Journal of Clinical Endocrinology & Metabolism 2024;109(6):1630-1655. doi.org/10.1210/clinem/dgad762
[3] Greff D, Juhász AE, Váncsa S, et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive Biology and Endocrinology 2023;21(1):10. doi.org/10.1186/s12958-023-01055-z
[4] Zhang J, Zhang H, Zhou W, Jiang M, Lin X. Effect of myo-inositol supplementation in mixed ovarian response IVF cohort: a systematic review and meta-analysis. Frontiers in Endocrinology 2025;16:1520362. doi.org/10.3389/fendo.2025.1520362
[5] Motuhifonua SK, Lin L, Alsweiler J, Crawford TJ, Crowther CA. Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes. Cochrane Database of Systematic Reviews 2023;2(2):CD011507. doi.org/10.1002/14651858.CD011507.pub3
